Snehal Jadhav

[LARVOL @Larvol]

Here are key cancer awareness dates and months to note in 2026 across oncology.

Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #Oncology #CancerCare #CancerAwarenes #BreastCancer #BCSM #LungCancer #LCSM #GICancer #GICSM #GUCancer #GUCSM #Melanoma #Lymphoma #Leukemia #MultipleMyeloma #HEMSM #MMSM #LEUSM #LYMSM #HeadAndNeckCancer #KindneyCancer #ColorectalCancer #BloodCancer

[LARVOL @Larvol]

EMERALD-1 trial: Updated data from @myESMO-GI 2026 in Unres HCC from Dr. Stephen L. Chan (@StephenLChan1) 👉 https://t.co/S1geZLDiux

Updated Landscape 👉 https://t.co/ZzwMEefgeO

Explore more insights and conference data from #ESMOGI26: https://t.co/VZ78kwriKk

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ESMOGI2026 #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #LiverCancer #GastricCancer #PancreaticCancer | @weoncologists | @ARosen380 | @ArndtVogel | @kmody29 | @ManniMD1

[Reena Thakur @5Reena_thakur]

🧘‍♀️ Happy International Yoga Day!
Twelve poses, one intention: a healthier body and a calmer mind ☀️🌞🧘🧘🧘
#InternationalYogaDay #SuryaNamaskar #YogaForWellness #HealthyBodyCalmMind #YogaEveryDay ☀️🧘‍♀️💜
@Larvol

[LARVOL @Larvol]

RUBY trial: 4-year update at @myESMO Gynecological Cancers 2026 in 1L mEndometrial from Dr. Mariana Carvalho Gouveia (@mcgouveia_) and Dr. Renata Colombo Bonadio (@renata_bonadio) et al 👉 https://t.co/bPEFq1yGTg

Updated Landscape: https://t.co/U3mtETZKm3

Get data-driven and real-time insights with CLIN 👉 https://t.co/ct6tMIQHii

#LARVOL #ESMOGynae26 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #GynecologicalCancers #Gynecology #EndometrialCancer #GynecologicOncology #Immunotherapy #GYNSM | @ShannonWestin | @DrKatyMoore | @nicoleflemingmd | @amandanfader | @David_Cohn_MD

[LARVOL @Larvol]

Updated DREAMM7 Data from @EHA_Hematology 2026 in R/R MM from @Larvol and Dr. Kamal Saini (@KSainiMD) 👉https://t.co/2wDT95bjOa

Updated Landscape: https://t.co/M0LyHrchfS

Explore more insights and data from #EHA2026 https://t.co/BsXE68zqmX

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @RahulBanerjeeMD | @HadidiSamer | @Abdallah81MD | @VincentRK

[LARVOL @Larvol]

Updated NX-5948-301 and CaDAnCe-101 Data from @EHA_Hematology 2026 in the 2L+ R/R CLL from Jacob Plieth (@JacobPlieth) 👉 https://t.co/lIDisqE2ov

Updated Landscape: https://t.co/ajE4eO3M6c

Explore more insights and data from #EHA2026 👉 https://t.co/BsXE68zqmX

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @calliecoombsmd | @TalhaBadarMD | @Papa_Heme | @Mohty_EBMT

[LARVOL @Larvol]

Top trending GI cancer trials on 𝕏 and key results from @ASCO 2026.

Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @marklewismd | @Erman_Akkus | @GIMedOnc | @ronanhsieh | @GillSharlene | @DaisukeKotani | @coffman_kelley | @DraMartinez | @Lagoryanhuey | @ArndtVogel

[LARVOL @Larvol]

Top trending ADC trials on 𝕏 and key results from @ASCO 2026.

Ranked by views of oncologist posts on clinical trials.

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #ADCs | @DrRishabhOnco | @PTarantinoMD | @dr_yakupergun | @Erman_Akkus | @StephenVLiu | @SuyogCancer | @tompowles1 | @DrKarineTawagi | @yekeduz_emre | @M_Torasawa

[LARVOL @Larvol]

Top trending Heme-Onc trials on 𝕏 and key results from @ASCO 2026.

Ranked by views of oncologist posts on clinical trials.

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @HadidiSamer | @bdermanmd | @VincentRK | @rajshekharucms | @HiraSMian | @TalhaBadarMD | @kansagraMD | @AgrimaMianMD | @RobertoMinaMD | @Mohty_EBMT

[LARVOL @Larvol]

Top trending lung cancer trials on 𝕏 and key results from @ASCO 2026.

Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #SCLC #esSCLC #NSCLC #LCSM | @M_Torasawa | @HHorinouchi | @lungoncdoc | @ADesaiMD | @StephenVLiu | @GlopesMd | @UOzkerim | @diegoadiazg | @Tony_Calles | @DrSanjayPopat

[LARVOL @Larvol]

Top trending BsAb trials on 𝕏 and key results from @ASCO 2026.

Ranked by views of oncologist posts on clinical trials.

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #BsAbs | @DrRishabhOnco | @M_Torasawa | @DrChoueiri | @HHorinouchi | @SuyogCancer | @PTarantinoMD | @Erman_Akkus | @StephenVLiu | @HadidiSamer | @ADesaiMD

[LARVOL @Larvol]

From bladder cancer to prostate and kidney cancer, several GU oncology studies are already generating strong attention ahead of @ASCO 2026.

To identify the trials most likely to shape discussions at the meeting, we asked leading AI models to rank the most anticipated GU cancer readouts.

There was particularly strong consensus around EV-302, PROTEUS, RAMPART, and TALAPRO-3 highlighting continued momentum for ADCs, radioligand therapy, immunotherapy combinations, and intensified hormonal strategies across GU cancers.

The list underscores key themes shaping the field:
▶️ Expansion of ADC and immunotherapy combinations in urothelial cancer
▶️ Continued evolution of AR-targeted and PARP-based approaches in prostate cancer
▶️ Growing momentum for radioligand and PSMA-targeted therapies
▶️ Increased focus on treatment optimization and de-escalation strategies
▶️ Novel approaches in RCC, NMIBC, and metastatic hormone-sensitive disease

Notable studies include:
• EV-302 evaluating enfortumab vedotin + pembrolizumab in metastatic urothelial cancer
• PROTEUS assessing apalutamide intensification in high-risk localized prostate cancer
• TALAPRO-3 advancing talazoparib-based combinations in HRR-altered mCSPC
• PSMAddition exploring 177Lu-PSMA-617 in PSMA-positive mHSPC
• RAMPART evaluating adjuvant durvalumab strategies in renal cell carcinoma

Together, these studies reflect how GU oncology continues to move toward more biomarker-driven, targeted, and combination-focused treatment strategies heading into ASCO 2026.

Which GU cancer trial are you watching most closely?

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUOncology #GUCancer #GUCSM #GenitourinaryCancer | @DrChoueiri | @neerajaiims | @AndreaNecchi | @UroDocAsh | @nataliagandur

[LARVOL @Larvol]

Updated HERIZON-GEA-01 data from @ASCO 2026 in 1L HER2+ Unresc/LA/m GC/GEJA landscape from Dr. Daniel Lin (@DanielLinMD) 👉 https://t.co/tTZD2ltSZo

Updated Landscape 👉 https://t.co/ZcjInsTZna

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #HERIZONGEA01 #GastricCancer #GastroesophagealJunctionCancer #GICSM | @SuyogCancer | @marklewismd | @CathyEngMD | @Erman_Akkus | @GillSharlene | @DaisukeKotani

[LARVOL @Larvol]

Updated CA209-9KU1 data from @ASCO 2026 in 1L mnccRCC landscape from Dr. Rana McKay (@DrRanaMcKay) 👉 https://t.co/JuPNwnFZ83

Updated Landscape: https://t.co/EiY8nAM5un

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #RenalCellCarcinoma #KidneyCancer #CA2099KU1 | @DrChoueiri | @neerajaiims | @AndreaNecchi | @DrYukselUrun | @montypal | @jgong15

[LARVOL @Larvol]

New ADVANCED-2 CR data from @AmerUrological (AUA) 2026 in H-grade NMIBC landscape from name Apex Onco 👉 https://t.co/HdxM7EZomB

Updated Landscape: https://t.co/zwkFow2Zlg

Learn more about ADVANCED-2 👉 https://t.co/wZQJaUqETC

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #AUA26 #UrologicOncology #Urology #NMIBC #BladderCancer #ADVANCED2 #SunRISe1 #BOND003 | @DrChoueiri | @UroDocAsh | @zklaassen_md | @JoshMeeks | @rksayyid

[LARVOL @Larvol]

Updated RMC-9805-001 data from @AACR 2026 in 2L+ KRAS G12D Adv NSCLC landscape from Dr. Amol Akhade (@SuyogCancer) 👉 https://t.co/xhPwojAyiN

Learn more about RMC-9805-001 ➡️ https://t.co/qvYW26GyRg

Explore more insights and data from #AACR26 👉 https://t.co/bMhp9sykLc

#LARVOL #AACR2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #NSCLC #LungCancer #LCSM #RMC9805001 | @StephenVLiu | @drgandara | @youngkwangchae | @Aiims1742 | @GIMedOnc

[LARVOL @Larvol]

@AACR 2026 Recap: Top Trials and Key Results

Explore more insights and data from #AACR26 👉 https://t.co/bMhp9sykLc

#LARVOL #AACR2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @Aiims1742 | @arnavmehta3 | @StephenVLiu | @DrRishabhOnco | @SuyogCancer | @DrMirallas | @GIMedOnc | @dr_yakupergun | @pashtoonkasi | @DavidHongMD

[LARVOL @Larvol]

Ahead of the @AACR 2026, we asked leading AI models to forecast outcomes for high-impact oncology trials ahead of the official AACR presentations.

We analyzed 22 trials, generating 40 predictions across key endpoints, along with 10 predicted Kaplan–Meier curves to visualize how outcomes may separate over time.

Each forecast includes hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, and AI-modeled Kaplan-Meier curves across tumor types.

Highlights:

Strong signals
IMCgp100-202 (Uveal Melanoma): Tebentafusp expected to sustain long-term survival benefit
▶️ AI consensus OS HR: 0.65

NCT05204628 (NSCLC): Dirozalkib projected to significantly improve PFS vs crizotinib
▶️ PFS HR: 0.46

NCT05969171 (Pancreatic Cancer): Surufatinib + chemotherapy shows promising PFS benefit
▶️ PFS HR: 0.67

Mixed / limited benefit
PRAGMATICA-LUNG (NSCLC): Ramu + pembrolizumab expected to show minimal OS improvement
▶️ OS HR: 0.96 (not significant)

Early-phase momentum (ORR signals)
Morpheus-Liver (HCC):
▶️ ORR: 41%

JS207-based combinations (HCC / mCRC):
▶️ ORR: up to ~50%

ZL-1310 (DLL3 ADC):
▶️ ORR: ~43%

Across trials, the AI consensus points to durable benefits in select targeted and immunotherapy approaches, strong early signals in next-generation combinations and ADCs, and continued variability in late-stage outcomes.

Which AACR 2026 results do you think will surprise us and which will the data confirm?

Explore more insights and data from #AACR26 👉 https://t.co/bMhp9sykLc

#LARVOL #AACR2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #UvealMelanoma #Melanoma #NSCLC #LungCancer #LCSM #PancreaticCancer #HepatocellularCarcinoma #HCC #SolidTumors #mCRC #GEC | @StephenVLiu | @ArndtVogel | @SuyogCancer | @CathyEngMD | @DrBetofMDPhD

[LARVOL @Larvol]

Ahead of the European Lung Cancer Congress 2026, we asked leading AI models to predict outcomes for key lung cancer trials. Now that the data is out, we compared those forecasts with actual results presented at ELCC 2026.

Important notes:
• Exact matches were suspected of data leakage due to being overly precise, so they were removed.
• Additional trials were also excluded because median values were not reported.

Where AI got it directionally right
HARMONi (IC PFS)
Ivonescimab + chemo showed strong benefit as predicted
▶️ AI: HR 0.36 | Actual: HR 0.53 (both significant)

LATIFY (OS)
Limited benefit correctly anticipated
▶️ AI: HR 0.98 (NS) | Actual: HR 0.90 (NS)

OptiTROP-Lung03 (OS)
Clear OS improvement captured
▶️ AI: HR 0.59 | Actual: HR 0.63 (both significant)

Where AI underestimated benefit

TOP (PFS)
Osimertinib + chemo outperformed expectations
▶️ AI: HR 0.65 | Actual: HR 0.44
▶️ Median PFS separation wider than forecast

Mixed alignment

NCT04143607 (OS)
Directional signal close, but significance not achieved
▶️ AI: HR 0.79 (NS) | Actual: HR 0.78 (NS)

Takeaways
• Across trials, AI forecasts:
• Captured directionality well (benefit vs. no benefit)
• Struggled with magnitude of effect (especially strong wins)
• Performed best in established mechanisms (IO, chemo combos)
• Showed more variance in targeted therapy settings

AI is increasingly reliable for signal detection, but less precise on effect size and separation, especially in high-impact trials.

What surprised you most at ELCC 2026 and which results most diverged from expectations?

Explore more insights and conference data from #ELCC26 👉 https://t.co/PuWKbMIQiA

#LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #ESSCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @MarioBalsaMD | @HHorinouchi | @bmassutis | @dplanchard | @JulienMazieres | @brunolarvol | @Davdwlkerson

[LARVOL @Larvol]

Updated CaDAnCe-101 data from JSMO 2026 in 2L+ R/R CLL landscape from Jacob Plieth 👉 https://t.co/lIDisqE2ov

Updated Landscape ⬇️: https://t.co/ajE4eO3M6c

Explore more insights and data with CLIN: https://t.co/HS6lBJuaYO

#LARVOL #JSMO26 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @DrRaulCordoba | @TaylorJ_MD | @calliecoombsmd | @victorshiyulin | @abouabdrahman0